Advertisement

 

 

Two-year Clinical Outcomes Post Implantation of Epic(TM) Self-Expanding Nitinol Stents for the Aortoiliac Occlusive Disease in Patients with Peripheral Arterial Disease.

Two-year Clinical Outcomes Post Implantation of Epic(TM) Self-Expanding Nitinol Stents for the Aortoiliac Occlusive Disease in Patients with Peripheral Arterial Disease.
Author Information (click to view)

Tsujimura T, Iida O, Fujita M, Masuda M, Okamoto S, Ishihara T, Nanto K, Kanda T, Okuno S, Matsuda Y, Fujihara M, Yokoi Y, Mano T,


Tsujimura T, Iida O, Fujita M, Masuda M, Okamoto S, Ishihara T, Nanto K, Kanda T, Okuno S, Matsuda Y, Fujihara M, Yokoi Y, Mano T, (click to view)

Tsujimura T, Iida O, Fujita M, Masuda M, Okamoto S, Ishihara T, Nanto K, Kanda T, Okuno S, Matsuda Y, Fujihara M, Yokoi Y, Mano T,

Advertisement

Journal of atherosclerosis and thrombosis 2017 10 05() doi 10.5551/jat.41152
Abstract
AIM
We investigated 2-year clinical outcomes after implantaton of Epic(TM) self-expanding nitinol stents for patients with peripheral artery disease (PAD) due to the aortoiliac occlusive disease (AIOD).

METHODS
This study was a multicenter and retrospective study. From February 2013 through October 2014, 292 lesions (chronic total occlusion, 21%; TASC Ⅱ C/D, 35%) in 217 consecutive patients (74±8 years; male, 81%; diabetes mellitus, 47%; dialysis, 21%; critical limb ischemia, 29%) who had undergone endovascular therapy (EVT) with Epic(TM) self-expanding nitinol stents for PAD with AIOD were analyzed. The primary endpoints were 2-year primary patency and target lesion revascularization (TLR)-free rate. The primary patency and freedom from TLR were determined by Kaplan-Meier analysis. Additionally, predictors for loss of patency were estimated by Cox proportional hazard model.

RESULTS
The mean follow-up duration was 19.1±8.5 months. Primary patency was 87.3% at 2 years. Freedom from TLR rate was 94.1% at 2 years. Multivariate analysis revealed that the presence of diabetes mellitus was associated with a loss of patency.

CONCLUSION
The Epic(TM) self-expanding nitinol stent was demonstrated to be safe and effectivene for AIOD when tested for two years in patients with PAD.

Submit a Comment

Your email address will not be published. Required fields are marked *

seven + 20 =

[ HIDE/SHOW ]